Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry

Diabetes Research and Clinical Practice
Barbara BohnDPV Initiative

Abstract

The long-acting insulin analogue degludec is a therapeutic option for patients with type 1 (T1D) or type 2 diabetes (T2D). Aim of this analysis was to investigate differences in clinical characteristics of patients before and after initiating degludec use in a cohort of German/Austrian patients. 1064 subjects with T1D/T2D and documented degludec use from the Diabetes-Patient-Follow-Up (DPV) registry were included. The follow-up cohort (n=421) comprised patients with available data before and 3-15months after switching to degludec. A t-test for paired values was implemented to compare rates of severe hypoglycaemia, and mean values for HbA1C, BMI, basal insulin dose/kg bodyweight/day, and the number of basal insulin injections/day before and after switching to degludec Results were stratified by type of diabetes. In T1D, subgroup analyses were conducted (age, sex, basal insulin used before switching). P<0.05 was considered significant. In T1D (n=360), basal insulin dose (0.43±0.17 to 0.38±0.13IU) and the number of basal injections/day (1.7±0.6 to 1.1±0.3) decreased whereas BMI increased from 23.2±4.8 to 24.0±5.0kg/m2 (all p<0.0001) after switching to degludec. No significant changes were observed regarding rates of severe hypogly...Continue Reading

Citations

Nov 11, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Paola PonzaniMaria Chiara Rossi
Sep 23, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Paola PonzaniMaria Chiara Rossi
Mar 27, 2019·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Shabnam ElahiMichelle Anne Van Name
Aug 10, 2019·The Journal of Clinical Endocrinology and Metabolism·Gian Paolo FadiniJohan Jendle
Oct 5, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Gian Paolo FadiniUNKNOWN REFLECT Italian Study Group
Mar 28, 2021·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Florentino Carral San LaureanoMaría Del Carmen Ayala Ortega

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.